Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2007-04-09
2009-12-15
Haq, Shafiqul (Department: 1641)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S409000, C436S528000, C436S111000, C436S823000, C564S305000
Reexamination Certificate
active
07632929
ABSTRACT:
The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.
REFERENCES:
patent: 4041076 (1977-08-01), Avenia et al.
patent: 4329281 (1982-05-01), Christenson et al.
patent: 4341758 (1982-07-01), Sakakibara et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5041076 (1991-08-01), Kantor
patent: 5135863 (1992-08-01), Hu et al.
patent: 5141850 (1992-08-01), Cole et al.
patent: 5160701 (1992-11-01), Brown, III et al.
patent: 5238652 (1993-08-01), Sun et al.
patent: 5328828 (1994-07-01), Hu et al.
patent: 5415994 (1995-05-01), Imrich et al.
patent: 5451504 (1995-09-01), Fitzpatrick et al.
patent: 5492841 (1996-02-01), Craig
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5559041 (1996-09-01), Kang et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5620890 (1997-04-01), Kamps-Holtzapple et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5690942 (1997-11-01), Hjorth
patent: 5976812 (1999-11-01), Huber et al.
patent: 6087184 (2000-07-01), Magginetti et al.
patent: 6306616 (2001-10-01), Shindelman
patent: 6669937 (2003-12-01), Owens et al.
patent: 7037669 (2006-05-01), Zheng et al.
patent: 7202348 (2007-04-01), Owens et al.
patent: 2003/0119083 (2003-06-01), Owens et al.
patent: 2003/0171435 (2003-09-01), Pouletty et al.
patent: 0239400 (1987-09-01), None
patent: 0343346 (1989-11-01), None
patent: 0574782 (1993-12-01), None
patent: 0375422 (1996-07-01), None
patent: 1331219 (2003-07-01), None
patent: 86/01533 (1986-03-01), None
patent: 92/03163 (1992-05-01), None
patent: 97/49732 (1997-12-01), None
patent: 01/81424 (2001-11-01), None
patent: 2004/050032 (2004-07-01), None
patent: 2007/147122 (2007-12-01), None
Albertson et al, “Methamphetamine and the Expanding Complications of Amphetamines”, West J. Med, 1999, pp. 214-219 vol. 170, No. 4.
Aoki et al, “Immunoassay For Methamphetamine With A New Antibody”, Forensic Science International, 1990, pp. 245-255, vol. 44.
Byrnes-Blake et al, “Generation of anti-(+)methamphetamine antibodies is not impeded by (+) methamphetamine administration during active immunization of rats”, International Immunopharmacology, 2001, pp. 329-338, vol. 1.
Byrnes-Blake et al, “Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats”, European Journal of Pharmacology, 2003, pp. 119-128, vol. 461.
Byrnes-Blake et al, “Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats”, European Journal of Pharmacology, 2005, pp. 86-94, vol. 521.
Chio et al, “Localization of the epitope in methamphetamine and its antibody use for the detection of methamphetamine and benzphetamine by polarization fluoroimmunoassay”, Journal of Immunoassy, 1995, pp. 263-278, vol. 16(3).
Cody et al, “Detection of D,L-Amphetamine, D,L-Methamphetamine, and Illicit Amphetamine Analogs Using Diagnostic Products Corporation's Amphetamine and Methamphetamine Radioimmunoassay”, Journal of Analytical Toxicology, 1990, pp. 321-324, vol. 14(5).
Colbert et al, “Single-Reagent Polarization Fluoroimmunoassay for Amphetamine in Urine” Clinical Chemistry, 1985, pp. 1193-1195, vol. 31, No. 7.
Cook et al, “Pharmacokinetic of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride”, Drug Metabolism and Dispositions, 1993, pp. 717-723, vol. 21, No. 4.
Danger et al, “Development of murine monoclonal antibodies to methamphetamine and methamphetamine analogues” , Journal of Immunological Methods, 2006, pp. 1-10, vol. 309.
Faraj et al, “Specificity of an Antibody Directed against d-Methamphetamine. Studies with Rigid and Nonrigid Analogs”, Journal of Medicinal Chemistry, 1976, pp. 20-25, vol. 19(1).
Farre et al, “Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics”, Psychopharmacology, 2004, pp. 364-375, vol. 173.
Hardin et al, “Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs”, The Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 1113-1122, vol. 285(3).
Kosten et al, “Immunotherapy for the treatment of drug abuse”, Pharmacology and Therapeutics, 2005, pp. 76-85 vol. 108.
Laurenzana et al, “Use of Anti-(+)-Methamphetamine Monoclonal Antibody To Significantly Alter (+)-Methamphetamine and (+)-Amphetamine Disposition In Rats”, Drug Metabolism and Disposition, 2003, pp. 1320-1326, vol. 31(11).
Li et al, “Four-choice drug discrimination in pigeons”, Behavioural Pharmacology, 2001, pp. 621-628, vol. 12.
McMillan et al, “Schedule control of quantal and graded dose-effect curves in a drug-drug-saline discrimination”, Pharmacology, Biochemistry and Behavior, 2001, pp. 395-402, vol. 68.
McMillian et al, “Discrimination of pentobarbital doses and drug mixtures under fixed-ratio and fixed-interval reinforcement schedules”, Behavioural Pharmacology, 2001, pp. 195-208, vol. 12.
McMillian et al, “Pharmacokinetic antagonism of (+)-methamphetamine discrimination by low-affinity monoclonal anti-methamphetamine antibody”, Behavioural Pharmacology, 2002, pp. 465-473, vol. 13.
McMillian et al, “Effects of Murine-Derived Anti-Methamphetamine Monoclonal Antibodies on (+)-Methamphetamine Self-Administration in the Rat”, Journal of Pharmacology and Experimental Therapeutics, 2004, pp. 1248-1255, vol. 309(3).
Nam et al, “Production and Characterization of Monoclonal Antibody That Simultaneously Recognizes Methamphetamine and Its Major Metabolite”, Biological and Pharmaceutical Bulletin, 1993 pp. 490-492, vol. 16(5).
Owens et al, “Antibodies Against Arylcyclohexylamines and Their Similarities in Binding Specificity with the Phencyclidine Receptor”, The Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 472-478 vol. 246(2).
Peterson et al, “Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse”, Journal of Pharmocology and Experimental Therapeutics, 2007 pp. 30-39, vol. 322(1).
Peterson et al., “Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse”,The AAPS Journal, 2006, pp. E383-E390, vol. 8(2).
Proksch et al. “Anti-Phencyclidine Monoclonal Antibodies Provide Long-Term Reductions in Brain Phencyclidine Concentrations during Chronic Phencyclidine Administration in Rats”, The Journal of Pharmacology and Experimental Therapeutics, 2000, pp. 831-837, vol. 292(3).
Richards et al., “Methamphetamine Abuse and Emergency Department Utilization”, West J Med, 1999, pp. 198-202, vol. 170, No. 4.
Riviere et al. “Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamhetamine and Its Metabolite Amphetamine in the Rat”, The Journal of Pharmacology and Experimental Therapeutics, 1999, pp. 1220-1226, vol. 291(3).
Riviere et al. “Disposition of Methamphetamine and Its Metabolite Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration”, The Journal of Pharmacology and Experimental Therapeutics, 2000, pp. 1042-1047, vol. 292, No. 3.
Suttijitpaisal et al., “Immunoassays of Amphetamines: Immunogen Structure vs Antibody Specificity”, Asian Pacific Journal of Allergy and Immunology, 1992, pp. 159-164, vol. 10.
Tempest et al. “Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in VIVO”, Biotechnology, 1991, pp. 266-271, vol. 9.
Tera
Abraham Philip
Carroll Frank Ivy
Owens Samuel M.
Haq Shafiqul
Polsinelli Shughart PC
The Board of Trustees of the University of Arkansas
LandOfFree
Methamphetamine-like hapten compounds, linkers, carriers and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methamphetamine-like hapten compounds, linkers, carriers and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methamphetamine-like hapten compounds, linkers, carriers and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113323